Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study

被引:52
作者
Takada, Tsuyoshi [1 ]
Sakata, Yasuhiko [1 ]
Miyata, Satoshi [2 ]
Takahashi, Jun [1 ]
Nochioka, Kotaro [1 ]
Miura, Masanobu [1 ]
Tadaki, Soichiro [1 ]
Shimokawa, Hiroaki [1 ,2 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Evidenced Based Cardiovasc Med, Sendai, Miyagi 9808574, Japan
关键词
Heart rate; Prognosis; Heart failure; CARDIOVASCULAR MORTALITY; EUROPEAN-SOCIETY; CONTROLLED-TRIAL; RATE REDUCTION; RISK-FACTOR; DYSFUNCTION; ASSOCIATION; IVABRADINE; CARVEDILOL; DIAGNOSIS;
D O I
10.1002/ejhf.22
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims It is still controversial whether elevated baseline heart rate (HR) is associated with higher mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF). We compared the impacts of baseline HR on mortality in patients with HFpEF and those with HF with reduced ejection fraction (HFrEF). Methods and results We enrolled consecutive 2688 patients in Stage C or D HF with sinus rhythm from our Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2) Study (n = 10 219). The prognostic impact of HR increase was compared between the two groups, defined as left ventricular ejection fraction of < 50% (HFrEF) and > 50% (HFpEF). Cox regression analysis revealed that elevated baseline HR was associated with increased all-cause mortality in both groups [hazard ratio for the highest tertile (HH) 1.77 in HFrEF, P = 0.008; HH1.82 in HFpEF, P = 0.001]. However, as for mode of death, elevated HR was associated with cardiovascular (CV) death in HFpEF (HH 2.17, P = 0.012), but the association was modest in HFrEF (HH1.49, P = 0.14): in particular, impact on HF death was different between HFpEF (HH 3.79, P = 0.020) and HFrEF (HH 1.07, P = 0.864). In contrast, the prognostic impact of baseline HR on non-CV death was noted only in patients with HFrEF. beta-Blocker therapy was associated with reduced HF mortality in HFrEF (hazard ratio 0.49, P = 0.038) but not in HFpEF (hazard ratio 0.64, P = 0.321). Conclusions Elevated HR was associated with increased CV death in HFpEF compared with HFrEF, although its impact on all-cause mortality was comparable between the two groups.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 30 条
[1]   The effects of β1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction -: A double-blind, placebo-controlled, positron-emission tomography study [J].
Beanlands, RSB ;
Nahmias, C ;
Gordon, E ;
Coates, G ;
deKemp, R ;
deKemp, R ;
Firnau, G ;
Fallen, E .
CIRCULATION, 2000, 102 (17) :2070-2075
[2]   Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study [J].
Boehm, Michael ;
Borer, Jeffrey ;
Ford, Ian ;
Gonzalez-Juanatey, Jose R. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Reil, Jan-Christian ;
Swedberg, Karl ;
Tavazzi, Luigi .
CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (01) :11-22
[3]  
Böhm M, 2010, LANCET, V376, P886, DOI 10.1016/S0140-6736(10)61259-7
[4]   Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation [J].
Bui, Anh L. ;
Grau-Sepulveda, Maria V. ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Yancy, Clyde W. ;
Bhatt, Deepak L. ;
Fonarow, Gregg C. .
AMERICAN HEART JOURNAL, 2013, 165 (04) :567-+
[5]   Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure [J].
Castagno, Davide ;
Skali, Hicham ;
Takeuchi, Madoka ;
Swedberg, Karl ;
Yusuf, Salim ;
Granger, Christopher B. ;
Michelson, Eric L. ;
Pfeffer, Marc A. ;
McMurray, John J. V. ;
Solomon, Scott D. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (20) :1785-+
[6]   Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice [J].
Custodis, Florian ;
Baumhaekel, Magnus ;
Schlimmer, Nils ;
List, Franka ;
Gensch, Christoph ;
Boehm, Michael ;
Laufs, Ulrich .
CIRCULATION, 2008, 117 (18) :2377-2387
[7]   Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties [J].
Dobre, Daniela ;
Borer, Jeffrey S. ;
Fox, Kim ;
Swedberg, Karl ;
Adams, Kirkwood F. ;
Cleland, John G. F. ;
Cohen-Solal, Alain ;
Gheorghiade, Mihai ;
Gueyffier, Francois ;
O'Connor, Christopher M. ;
Fiuzat, Mona ;
Patak, Athul ;
Pina, Ileana L. ;
Rosano, Giuseppe ;
Sabbah, Hani N. ;
Tavazzi, Luigi ;
Zannad, Faiez .
EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (01) :76-85
[8]   Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial [J].
Fox, Kim ;
Ford, Ian ;
Steg, P. Gabriel ;
Tendera, Michal ;
Robertson, Michele ;
Ferrari, Roberto .
LANCET, 2008, 372 (9641) :817-821
[9]   Clinical Effectiveness of Beta-Blockers in Heart Failure Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry [J].
Hernandez, Adrian F. ;
Hammill, Bradley G. ;
O'Connor, Christopher M. ;
Schulman, Kevin A. ;
Curtis, Lesley H. ;
Fonarow, Gregg C. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (02) :184-192
[10]   HEART-RATE AND CARDIOVASCULAR MORTALITY - THE FRAMINGHAM-STUDY [J].
KANNEL, WB ;
KANNEL, C ;
PAFFENBARGER, RS ;
CUPPLES, LA .
AMERICAN HEART JOURNAL, 1987, 113 (06) :1489-1494